指南与共识性腺与生殖内分泌

肌醇治疗多囊卵巢综合征:为2023年国际循证PCOS指南更新提供依据的系统评价与Meta分析

Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.
指南 / 共识 · J Clin Endocrinol Metab · 2024-01-01

该系统评价与Meta分析评估肌醇单用或联合治疗多囊卵巢综合征的疗效,纳入30项试验(n=2230,干预组1093例,对照组1137例),其中19项被纳入Meta分析。证据提示肌醇对部分代谢指标有益,DCI可能对排卵有益,但肌醇对其他结局可能无效。支持肌醇用于PCOS管理的证据有限且不确定,临床决策应结合证据不确定性与患者个体价值观和偏好。

要点

  • 肌醇对部分代谢指标有益,DCI可能对排卵有益,但对其他结局可能无效。
  • 与肌醇相比,二甲双胍可能改善腰臀比和多毛症,但生殖结局可能无差异。
  • 肌醇与二甲双胍相比可能引起较少的胃肠道不良事件,且通常轻微且自限。

核心结论

  • 支持肌醇用于PCOS管理的证据有限且不确定。
  • 临床医生和患者在使用肌醇治疗PCOS进行共享决策时,应考虑证据的不确定性以及个体价值观和偏好。

研究设计与样本

  • 系统评价与Meta分析,纳入30项试验(n=2230;干预组1093例,对照组1137例),其中19项纳入Meta分析。
  • 检索Medline、PsycInfo、EMBASE、All EBM和CINAHL,从建库至2022年8月。
  • 由1名评价者提取激素、代谢、血脂、心理、人体测量、生殖结局和不良反应数据,并由第2名评价者独立核实。

主要发现

  • 评估了13项比较,其中3项纳入Meta分析。
  • 证据提示肌醇(myo-inositol)或D-手性肌醇(DCI)对某些代谢指标有益,DCI对排卵可能有潜在益处,但肌醇对其他结局可能无影响。
  • 与肌醇相比,二甲双胍可能改善腰臀比和多毛症,但生殖结局可能无差异,体重指数(BMI)的证据非常不确定。
  • 与二甲双胍相比,肌醇可能引起较少的胃肠道不良事件;然而,这些事件通常轻微且自限。

临床怎么用

  • 临床医生和患者在使用肌醇治疗PCOS进行共享决策时,应考虑证据的不确定性以及个体价值观和偏好。

局限性

  • 支持肌醇用于PCOS管理的证据有限且不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Insulin resistance is common in women with polycystic ovary syndrome (PCOS). Inositol may have insulin sensitizing effects; however, its efficacy in the management of PCOS remains indeterminate. OBJECTIVE: To inform the 2023 international evidence-based guidelines in PCOS, this systematic review and meta-analysis evaluated the efficacy of inositol, alone or in combination with other therapies, in the management of PCOS. DATA SOURCES: Medline, PsycInfo, EMBASE, All EBM, and CINAHL from inception until August 2022. STUDY SELECTION: Thirty trials (n = 2230; 1093 intervention, 1137 control), with 19 pooled in meta-analyses were included. DATA EXTRACTION: Data were extracted for hormonal, metabolic, lipids, psychological, anthropometric, reproductive outcomes, and adverse effects by 1 reviewer, independently verified by a second. DATA SYNTHESIS: Thirteen comparisons were assessed, with 3 in meta-analyses. Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes. Metformin may improve waist-hip ratio and hirsutism compared to inositol, but there is likely no difference for reproductive outcomes, and the evidence is very uncertain for body mass indexI. Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin; however, these are typically mild and self-limited. CONCLUSION: The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive. Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fitz V, Graca S, Mahalingaiah S, et al. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024. PMID: 38163998. doi:10.1210/clinem/dgad762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。